KRAS is a small GTPase that belongs to the family of RAS oncogenes. It is involved in a number of biological processes, including cell survival, proliferation, and metabolism. Numerous cancer subtypes have mutations in KRAS, which cause unchecked cell growth and changes in cell metabolism. Thus, in cancer cells, KRAS contributes to the Warburg effect. KRAS binds to GDP in its inactive form and to GTP in its active form, just like most other small GTPases.

The AlphaLISA SureFire Ultra Human Total KRAS Detection Kit is a sandwich immunoassay for the quantitative detection of total KRAS in cellular lysates, using Alpha Technology.

 Formats:

• The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
• The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
• The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
• The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

• Cell and tissue lysates
• Antibody modulators
• Biotherapeutic antibodies

Alpha SureFire kits can be used for:

• Cellular kinase assays
• Receptor activation studies
• Screening